Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230282 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Steven E. Coutre.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00230282 is a Phase 2 study that has completed, run by Steven E. Coutre. The registered enrollment target is 25 participants.
The verdict
NCT00230282, a Phase 2 study, has completed, sponsored by Steven E. Coutre.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.
Interventions
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230282
The ClinicalTrials.gov registry entry for NCT00230282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven E. Coutre, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00230282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230282 about?
NCT00230282 is a clinical study titled "Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia". The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.
What is the current status of trial NCT00230282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00230282?
The interventions under investigation include: Fludarabine (DRUG), Alemtuzumab (DRUG), Cytoxan (DRUG).
Who is sponsoring clinical trial NCT00230282?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.